Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

[1]  A. Perelson,et al.  Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model , 2001, Hepatology.

[2]  G. Davis,et al.  Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C , 2000, Hepatology.

[3]  H. Conjeevaram,et al.  A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype , 2000, American Journal of Gastroenterology.

[4]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[5]  O. Weiland,et al.  Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. , 1999, Gastroenterology.

[6]  A. Alberti,et al.  Comparison of thrice weekly vs daily human leucocyte interferon‐α therapy for chronic hepatitis C , 1999, Journal of viral hepatitis.

[7]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[8]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[9]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[10]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[11]  H. Van Vlierberghe,et al.  Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. , 1998, Journal of hepatology.

[12]  Aril Frydén,et al.  Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.

[13]  S. Emerson,et al.  Therapy of hepatitis C: Meta‐analysis of interferon alfa‐2b trials , 1997, Hepatology.

[14]  W. Cooksley,et al.  Efficacy and tolerance of a 6‐month treatment course of daily interferon‐α2a for chronic hepatitis C with cirrhosis , 1997, Journal of viral hepatitis.

[15]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[16]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[17]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[18]  J. Schmidt,et al.  Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo , 1996, Hepatology.

[19]  J. Albrecht,et al.  Quantitative detection of hepatitis C virus RNA with a solid‐phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon‐treated patients , 1994, Hepatology.